Patents Assigned to University of Texas Systems
  • Patent number: 11645835
    Abstract: A method and system for creating hypercomplex representations of data includes, in one exemplary embodiment, at least one set of training data with associated labels or desired response values, transforming the data and labels into hypercomplex values, methods for defining hypercomplex graphs of functions, training algorithms to minimize the cost of an error function over the parameters in the graph, and methods for reading hierarchical data representations from the resulting graph. Another exemplary embodiment learns hierarchical representations from unlabeled data. The method and system, in another exemplary embodiment, may be employed for biometric identity verification by combining multimodal data collected using many sensors, including, data, for example, such as anatomical characteristics, behavioral characteristics, demographic indicators, artificial characteristics.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: May 9, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Aaron Benjamin Greenblatt, Sos S. Agaian
  • Patent number: 11642671
    Abstract: A method and system for performing biomolecule extraction are provided that use liquid-to-liquid extraction (LLE) in combination with an electrowetting on dielectric (EWOD) device to provide a biomolecule extraction solution that has high extraction efficiency and that is less costly and easier to use than current state of the art methods and systems. The system and method are well suited for, but not limited to, extraction of DNA, RNA and protein molecules.
    Type: Grant
    Filed: June 27, 2022
    Date of Patent: May 9, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Hyejin Moon, Shubhodeep Paul
  • Patent number: 11642849
    Abstract: Bio-Inks and methods of using compositions comprising the bio-Inks are disclosed. 3-D tissue repair and regeneration through precise and specific formation of biodegradable tissue scaffolds in a tissue site using the bio-inks are also provided. Specific methylacrylated gelatin hydrogels (MAC) and methacrylated chitosan (MACh) preparations formulated with sucrose, a silicate-containing component (such as laponite), and/or a cross-linking agent (such as a photo-initiator or chemical initiator), as well as powdered preparations of these, are also disclosed. Kits containing these preparations are provided for point-of-care tissue repair in vivo. Superior, more complete (up to 99.85% tissue regeneration within 4 weeks applied in situ), and rapid in situ tissue repair and bone formation are also demonstrated.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: May 9, 2023
    Assignees: The Texas A&M University System, The Board of Regents, The University of Texas System
    Inventors: Venu G. Varanasi, Azhar Ilyas, Philip Roger Kramer, Taha Azimaie, Pranesh B. Aswath, Tugba Cebe
  • Patent number: 11644380
    Abstract: An integrated rapid infrastructure monitoring system for identifying defects in an underlying surface, comprising: at least one actuator; and, at least one impactor operatively connected to the actuator, wherein the actuator is configured to transition the integrated rapid infrastructure monitoring system from a first configuration with at least one of a motive force and an impact bounce force of the impactor, where the impactor is located on a first side of the integrated rapid infrastructure monitoring system, to a second configuration, where the impactor is located on a second side of the integrated rapid infrastructure monitoring system.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: May 9, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventor: Suyun Ham
  • Publication number: 20230139944
    Abstract: Provided herein, in some aspects, are agents, such as antibodies, chimeric antigen receptors, or RNA interference molecules that target the interaction between ?3?1 integrin and ?1 homotrimeric type I collagen. Aspects are directed to methods of treating cancer and fibroids comprising administering to a patient in need thereof an effective amount of an agent that disrupts the interaction between ?3?1 integrin and ?1 homotrimeric type I collagen. The methods can further include administering an effective amount of chemotherapy or immunotherapy to said patient.
    Type: Application
    Filed: June 17, 2020
    Publication date: May 4, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventor: Raghu KALLURI
  • Publication number: 20230139394
    Abstract: A method of electroencephalography (EEG) based speech recognition includes obtaining, from a microphone, an audio signal of a speaker from a first time period, obtaining, from one or more EEG sensors, EEG signals of the speaker from the first time period, obtaining, from a first model, acoustic representations based on the EEG signals, concatenating the obtained acoustic representations with an audio input based on the audio signal to obtain concatenated features, providing the concatenated features to an automatic speech recognition model (ASR) and obtaining, from the ASR model, a text-based output.
    Type: Application
    Filed: January 11, 2022
    Publication date: May 4, 2023
    Applicants: Austin Speech Labs, LLC, Board of Regents, the University of Texas System
    Inventors: Gautam Krishna, Mason Carnahan, Amrit Chandar, Shilpa Shamapant, Ahmed Tewfik, José del R. Millán
  • Patent number: 11638611
    Abstract: In one embodiment, a system for locating a tip of a catheter that has been inserted into a patient includes an implantable catheter having a distal tip, a pulsed light source that is co-located with the distal tip of the implantable catheter, the pulsed light source being configured to emit pulses of light into surrounding patient tissue, an optoacoustic sensor configured to be applied so a skin surface of the patient at a position proximate to the pulsed light source and to sense optoacoustic waves generated when the pulses of light are absorbed by the surrounding patient tissue, and an optoacoustic console configured to receive optoacoustic wave signals from the optoacoustic sensor and to display an indication of the optoacoustic wave signals to a medical professional to provide an indication of the location of the pulsed light source and, therefore, the distal tip of the implantable catheter.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: May 2, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Rovnat Babazade, Yuriy Petrov, Irene Petrov, Rinat O. Esenaliev
  • Patent number: 11638816
    Abstract: A nerve cuff electrode device comprising a cuff body having a smart memory polymer layer with a rigid configuration at room temperature and a softened configuration at about 37° C. The smart memory polymer layer has a trained curved region with a radius of curvature of about 3000 microns or less. A plurality of thin film electrodes located on the smart memory polymer layer. The thin film electrodes include discrete titanium nitride electrode sites that are located in the trained curved region. An exposed surface of each of the discrete titanium nitride electrode sites has a charge injection capacity of about 0.1 mC/cm2 or greater. Methods or manufacturing and using the device are also disclosed.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: May 2, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Romil Modi, Walter E. Voit, Mario Romero-Ortega
  • Publication number: 20230130134
    Abstract: The present invention relates to methods of treating and preventing viral diseases and infections comprising the administration of hexoses and analogs and their prodrugs thereof that inhibit glycolysis and/or glycosylation.
    Type: Application
    Filed: March 16, 2021
    Publication date: April 27, 2023
    Applicants: Board of Regents, The University of Texas System, Moleculin Biotech, Inc.
    Inventors: Waldemar PRIEBE, Izabela FOKT, Rafal ZIELINSKI, Stanislaw SKORA, Donald PICKER, Walter KLEMP
  • Publication number: 20230128075
    Abstract: Provided herein are agents, such as antibodies and chimeric antigen receptors, that target HSP70. Methods of treating cancer are provided, comprising administering to a patient in need thereof an effective amount of an HSP70-targeting agent. The HSP70-specific antibody may enhance uptake of HSP70 by antigen presenting cells.
    Type: Application
    Filed: March 26, 2021
    Publication date: April 27, 2023
    Applicants: Board of Regents, The University of Texas System, Asylia Therapeutics
    Inventors: Robert Z. ORLOWSKI, Richard J. JONES, Laura C. BOVER, Jeno GYURIS, John MILLER, James Bernard McCLORY, Darragh MAC CANN, William M. WINSTON, SR.
  • Patent number: 11633623
    Abstract: A method and apparatus for radiation therapy using functional measurements of branching structures. The method includes determining a location of each voxel of a plurality of voxels in a reference frame of a radiation device. The method further includes obtaining measurements that indicate a tissue type at each voxel. The method further includes determining a subset of the voxels based on an anatomical parameter of a respective branching structure of a set of branching structures indicated by the measurements. The method further includes determining a subset of the voxels that enclose an organ-at-risk (OAR) volume. The method further includes determining a value of a utility measure at each voxel. The method further includes determining a series of beam shapes and intensities which minimize a value of an objective function based on a computed dose delivered to each voxel and the utility measure for that voxel summed over all voxels.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: April 25, 2023
    Assignees: University of Maryland, Baltimore, The Board of Regents of the University of Texas System, Broncus
    Inventors: Amit Sawant, Robert Timmerman, Yulong Yan, Henky Wibowo, Esther Vicente, Arezoo Modiri
  • Publication number: 20230121116
    Abstract: Provided herein are methods of selecting cancer patients for treatment with quinazoline-based tyrosine kinase inhibitors, either alone or in combination with anti-HER2/HER3 antibodies, as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with quinazoline-based tyrosine kinase inhibitors alone or in combination with anti-HER2/HER3 antibodies.
    Type: Application
    Filed: January 29, 2021
    Publication date: April 20, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: John HEYMACH, Jacqulyne ROBICHAUX
  • Publication number: 20230122024
    Abstract: Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.
    Type: Application
    Filed: October 21, 2022
    Publication date: April 20, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jef De Brabander, Daniel Rosenbaum, Qiren Liang, Wentian Wang
  • Patent number: 11631502
    Abstract: In an embodiment, a simulation of the evolution of a tumor in a prostate gland of a subject is based at least on a coupled system of reaction-diffusion equations and a patient-specific geometric model of the prostate gland of the subject. The use of reaction-diffusion equations and a patient-specific geometric model provides a tumor model that predicts the expected progression of prostate cancer in the subject. The tumor model may be used to devise a customized treatment for the subject.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: April 18, 2023
    Assignees: Board of Regents, The University of Texas System, University of A Coruna
    Inventors: Thomas J. R. Hughes, Hector Gomez, Guillermo Lorenzo
  • Publication number: 20230113170
    Abstract: SARS-CoV-2 S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the SARS-CoV-2 S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to SARS-CoV-2 S in a subject, for example, an immune response that inhibits SARS-CoV-2 infection in the subject.
    Type: Application
    Filed: February 11, 2021
    Publication date: April 13, 2023
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human, Board of Regents, The University of Texas System, Trustees of Dartmouth College
    Inventors: Barney Graham, Kizzmekia Corbett, Olubukola Abiona, Geoffrey Hutchinson, Jason McLellan, Daniel Wrapp, Nianshuang Wang
  • Publication number: 20230112470
    Abstract: Provided herein are methods of selecting cancer patients for treatment with a covalent EGFR/HER2 TKI, a HER2/HER3 targeting antibody, or a combination of a covalent EGFR/HER2 TKI and a HER2/HER3 targeting antibody as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with a covalent EGFR/HER2 TKI, a HER2/HER3 targeting antibody, or a combination of a covalent EGFR/HER2 TKI and a HER2/HER3 targeting antibody.
    Type: Application
    Filed: January 29, 2021
    Publication date: April 13, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: John HEYMACH, Jacqulyne ROBICHAUX
  • Patent number: 11624050
    Abstract: Disclosed is the design, fabrication, and characterization of a novel system comprising a parallel set of nanopore microneedles (NPMs) for cell transfection through controlled nanoelectroporation (NEP) and electrophoretic insertion of genetic materials.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: April 11, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Lingqian Chang, R. Lyle Hood, Forhad Akhter
  • Patent number: 11623396
    Abstract: The present disclosure relates to a tensioning system for use in a stereolithography manufacturing application. The system may have a build plate for supporting a three dimensional part being formed using a photo responsive resin, a base plate and a release element extending over the base plate. The release element is configured to receive a quantity of photo responsive resin for forming a new material layer of the three dimensional part. A pair of tensioning components are secured to opposite ends of the release element, and apply a controlled tension force to the release element during peeling of the release element to reduce a separation force required to separate the release element from the new material layer after the new material layer is cured.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: April 11, 2023
    Assignees: Lawrence Livermore National Security, LLC, Board of Regents, The University of Texas System
    Inventors: Eric B. Duoss, James Oakdale, Nicholas Anthony Rodriguez, Hongtao Song, Richard Crawford, Carolyn Seepersad, Morgan Chen
  • Publication number: 20230106973
    Abstract: Provided herein are methods for the activation and expansion of genetically-modified Tcells, such as tumor infiltrating lymphocytes. In some cases, cells of the embodiments can be used for the therapeutic treatment of human diseases, such as cancer.
    Type: Application
    Filed: February 16, 2021
    Publication date: April 6, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Marie-Andrée FORGET, Chantale BERNATCHEZ, Cara HAYMAKER, Michael A. CURRAN, Patrick HWU, Cassian YEE
  • Patent number: RE49514
    Abstract: Provided herein are methods for using compositions that include a fusion protein having a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. In one embodiment the composition is used to confer immunity to plague, such as pneumonic plague, caused by Yersinia pestis. In one embodiment, the composition is administered to a mucosal surface, such as by an intranasal route. In one embodiment, the administration to a mucosal surface includes a vector that has a polynucleotide encoding a fusion protein, where the fusion protein includes a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. The administration is followed by a second administration by a different route, such as an intramuscular route. The second administration includes a fusion protein having the same three domains, and in one embodiment the fusion protein is the same one administered to a mucosal surface.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: May 2, 2023
    Assignees: The Board of Regents of the University of Texas System, Westport Bio, LLC
    Inventors: Ashok K. Chopra, Vladimir L. Motin, Eric Rothe